Prof Mateos speaks with ecancer at the 2017 ASH annual meeting about the first randomised trial looking to evaluate the use of a monoclonal antibody drug daratumumab, for treating newly diagnosed multiple myeloma. The study highlighted that adding daratumumab to one standard treatment regimen (bortezomib, melphalan, and prednisone) reduced the likelihood of disease progression or death by 50 percent.
For more information read the news story.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.